Investors sold shares of Intrexon Corp (NYSE:XON) on strength during trading on Tuesday. $3.74 million flowed into the stock on the tick-up and $28.12 million flowed out of the stock on the tick-down, for a money net flow of $24.38 million out of the stock. Of all equities tracked, Intrexon had the 0th highest net out-flow for the day. Intrexon traded up $0.31 for the day and closed at $9.81

A number of brokerages have recently commented on XON. ValuEngine upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. JMP Securities raised their price objective on shares of Intrexon from $42.00 to $43.00 and gave the stock a “market outperform” rating in a research report on Wednesday, October 10th. Finally, Zacks Investment Research cut shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Monday, October 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $29.67.

Intrexon (NYSE:XON) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.21). The company had revenue of $32.45 million for the quarter, compared to analysts’ expectations of $35.98 million. During the same period in the prior year, the firm posted ($0.33) EPS. The company’s revenue was down 29.5% compared to the same quarter last year.

In related news, SVP Joel D. Liffman sold 79,000 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $14.59, for a total transaction of $1,152,610.00. Following the completion of the sale, the senior vice president now directly owns 79,500 shares in the company, valued at $1,159,905. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 48.20% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in Intrexon during the third quarter worth about $131,000. Tower Research Capital LLC TRC purchased a new position in Intrexon during the third quarter worth about $151,000. Pacer Advisors Inc. purchased a new position in Intrexon during the third quarter worth about $162,000. Tocqueville Asset Management L.P. purchased a new position in Intrexon during the third quarter worth about $172,000. Finally, Redmond Asset Management LLC purchased a new position in Intrexon during the third quarter worth about $178,000. 84.92% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Investors Sell Shares of Intrexon (XON) on Strength (XON)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/11/21/investors-sell-shares-of-intrexon-xon-on-strength-xon.html.

Intrexon Company Profile (NYSE:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Recommended Story: Average Daily Trade Volume Explained

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.